KPAX002-1: Alzheimer's Disease

Following the failure of multiple efforts to target beta amyloid, we need to be focusing on alternative mechanisms to address Alzheimer's disease. There is now growing body of evidence linking mitochondrial dysfunction in genetically susceptible individuals to the progressive cognitive decline seen in patients with Alzheimer's disease (AD). Despite an abundance of scientific evidence supporting this mechanism, no Pharma company is currently pursuing a treatment utilizing the mitochondria as a therapeutic target. 

KPAX002 is a mitochondrial stimulant comprised of two components, both of which improve neuronal function.  The first component consists of a proprietary mitochondrial modulator compound well known to broadly support mitochondrial health and function. The second component consists of a low dose stimulant drug that acts to quickly improve the apathy, fatigue and cognitive slowing that are common AD symptoms. When combined, these two components exert a potent synergistic effect that promotes stabilization and improvement of AD symptoms.

We are prepared to implement a Phase 2 POC trial to investigate the feasibility of this patented compound to become the first disease modifying treatment for Alzheimer’s disease. KPAX002 can also be used as part of combination therapy to enhance the effectiveness of treatments based on other mechanisms of action (i.e. beta and gamma-secretase inhibitors).

There is strong scientific evidence supporting the potential for this compound to be effective as a disease modifying therapy for AD and, by making use of a 505(b)2 regulatory pathway, the path to approval would be significantly expedited. 

KPAX002-2: Parkinson's Disease  

We have successfully developed a mitochondrial modulator technology platform that treats the significant mitochondrial dysfunction inherent in Parkinson’s disease. This technology makes use of several key compounds that exert a synergistic effect on restoring healthy mitochondrial function and promoting improved neuronal health.

Our research indicates that KPAX002 has strong potential to delay Parkinson’s disease progression and begin PD patients on the road toward improvement and recovery by reducing both motor and non-motor PD symptoms

KPAX002 is a patented, clinical-stage asset that has demonstrated safety and strong efficacy in four clinical trials to date.

KPAX002 is patented through 2032. 

KPAX002-3:  Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by the death of upper and lower motor neurons leading to progressive paralysis. 

The pathological changes in ALS include significant abnormalities in mitochondrial morphology and functioning. Mounting evidence currently suggests that impaired mitochondrial function could be driving the ALS disease process and a key therapeutic target. 

KPAX002 is a mitochondrial rescue therapy directed at reducing mitochondrial stress and restoring the health of motor neurons in ALS patients. We believe this treatment has strong potential to modify the course of this debilitating disease.

We are currently prepared to implement a Phase 2a trial to investigate KPAX002 as a potential disease-modifying treatment for ALS, either as a stand alone therapy or in combination with current treatments.